Elusys Delivers Second Anthrax Treatment Batch to US Strategic National Stockpile Program
Elusys Therapeutics has delivered a second batch of monoclonal antibody injections designed for inhalation anthrax treatment to the Strategic National Stockpile after the company received $16.35 million in funds as part of a potential $45 million procurement contract from the U.S. government. The company said Tuesday its ANTHIM injection contains a neutralizing toxin that works to help prevent the spread of anthrax and potential tissue damage in the human body. […] More